Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO)

Q: What does CUSIP 019770106 represent in this 13F holders report?

CUSIP 019770106 is the security identifier for ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share in Q1 2026?

42 institutional investors reported ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 019770106

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, $0.001 par value per share
Shares outstanding: 344,793,745
Total 13F shares: 8,943,122
Share change: +2,545,057
Total reported value: $21,672,707
Price per share: $2.44
Number of holders: 42
Value change: +$6,255,358
Number of buys: 23
Number of sells: 7

Quarterly Holders Quick Answers

What is CUSIP 019770106?
CUSIP 019770106 identifies ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 019770106:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
TPG GP A, LLC	3/4/5 13F	10%+ Owner · Company	5.4% from 13F	18,716,306	$59,413,042	—	12 Jan 2022	3/4/5 13F
PFIZER INC	13F 13D/G	Company	9% from 13D/G	22,032,040	$30,183,895	—	31 Dec 2025	13F 13D/G
BlackRock, Inc.	13F 13D/G	Company	5.3% from 13D/G	17,676,029	$24,216,160	—	31 Dec 2025	13F 13D/G
Arie Belldegrun	13D/G 3/4/5	Arie Belldegrun, M.D. · Director	5.8%	13,248,170	$18,149,993	+$794,362	31 Dec 2025	13D/G 3/4/5
Lynx1 Capital Management LP	13D/G	—	5.2%	10,874,723	$16,747,073	$0	31 Dec 2024	13D/G
CITADEL ADVISORS LLC	13F 13D/G	Company · Kenneth Griffin	6.1% from 13D/G	12,111,420	$16,592,646	—	31 Dec 2025	13F 13D/G
David D. Chang	13D/G 3/4/5	David D. Chang, M.D., Ph.D. · President and CEO, Director	5.2%	12,101,223	$16,578,676	+$1,186,838	31 Dec 2025	13D/G 3/4/5
FMR LLC	13D/G 13F	Company	4.9%	10,225,851	$15,747,811	-$20,861,062	28 Feb 2025	13D/G 13F
VANGUARD GROUP INC	13F	Company	2.7%	9,251,609	$12,674,704	—	31 Dec 2025	13F
PRIMECAP MANAGEMENT CO/CA/	13F	Company	2.4%	8,139,840	$11,151,581	—	31 Dec 2025	13F
Patient Square Capital LP	13F	Company	1.4%	4,963,756	$6,800,346	—	31 Dec 2025	13F
Eric Thomas Schmidt	3/4/5	Chief Financial Officer	— mixed-class rows	2,447,772 mixed-class rows	$6,396,524	—	22 Mar 2023	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.1%	3,932,910	$5,388,905	—	31 Dec 2025	13F
Frazier Life Sciences Management, L.P.	13F	Company	1.1%	3,868,750	$5,300,188	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	1%	3,500,499	$4,795,684	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.99%	3,423,441	$4,690,114	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.93%	3,209,275	$4,398,000	—	31 Dec 2025	13F
Wildcat Capital Management, LLC	13F	Company	0.85%	2,920,787	$4,001,478	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.84%	2,890,200	$3,959,574	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.8%	2,761,400	$3,783,118	—	31 Dec 2025	13F
Kalehua Capital Management LLC	13F	Company	0.74%	2,546,129	$3,488,197	—	31 Dec 2025	13F
S.c.a. Candriam	13F	Individual	0.67%	2,305,644	$3,158,867	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.66%	2,289,458	$3,136,557	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.63%	2,187,084	$2,996,305	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.63%	2,160,383	$2,959,725	—	31 Dec 2025	13F
Aberdeen Group plc	13F	Company	0.61%	2,086,332	$2,858,275	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.53%	1,841,307	$2,522,591	—	31 Dec 2025	13F
Mr. Geoffrey Parker	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	1,944,347 mixed-class rows	$2,204,919	-$88,411	02 Feb 2026	3/4/5
Alison Moore	3/4/5	Chief Technical Officer	— mixed-class rows	1,105,469 mixed-class rows	$2,135,517	—	22 Mar 2023	3/4/5
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.41%	1,429,247	$1,958,068	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.4%	1,389,593	$1,903,743	—	31 Dec 2025	13F
DAFNA Capital Management LLC	13F	Company	0.4%	1,380,118	$1,890,762	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.39%	1,355,809	$1,857,458	—	31 Dec 2025	13F
Veer Bhavnagri	3/4/5	General Counsel	— class O/S missing	556,049	$1,765,122	—	14 Mar 2023	3/4/5
D. E. Shaw & Co., Inc.	13F	Company	0.37%	1,282,971	$1,757,670	—	31 Dec 2025	13F
Rafael Amado	3/4/5	EVP of R&D	— class O/S missing	541,946	$1,720,353	—	07 Oct 2022	3/4/5
NORTHERN TRUST CORP	13F	Company	0.35%	1,198,467	$1,641,899	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.29%	1,007,328	$1,380,039	—	31 Dec 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.29%	995,141	$1,360,000	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.28%	979,112	$1,341,384	—	31 Dec 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.28%	957,816	$1,311,538	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.26%	900,424	$1,233,581	—	31 Dec 2025	13F
Raiffeisen Bank International AG	13F	Company	0.26%	900,000	$1,179,000	—	31 Dec 2025	13F
Zachary Roberts	3/4/5	EVP of R&D	— mixed-class rows	1,503,236 mixed-class rows	$1,028,663	-$104,169	02 Feb 2026	3/4/5
Earl Martin Douglas	3/4/5	SVP, General Counsel	— mixed-class rows	1,256,500 mixed-class rows	$994,308	-$40,304	02 Feb 2026	3/4/5
MORGAN STANLEY	13F	Company	0.2%	703,138	$963,298	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.19%	642,687	$880,481	—	31 Dec 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.18%	613,998	$841,000	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.18%	609,807	$835,436	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0.17%	591,952	$810,974	—	31 Dec 2025	13F

Institutional Holders of Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO) as of Q1 2026

As of 31 Mar 2026, Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO) was held by 42 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 8,943,122 shares. The largest 10 holders included Candriam S.C.A., Nuveen, LLC, Aberdeen Group plc, Raiffeisen Bank International AG, Harold Davidson & Associates Inc., HSBC HOLDINGS PLC, Tema ETFs LLC, PROFUND ADVISORS LLC, WEALTH ENHANCEMENT ADVISORY SERVICES, LLC, and Navalign, LLC. This page lists 42 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

169

Q1 2026 holders

Holder diff

-127

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.